Epeius Biotechnologies Corporation News from Send2Press Newswire

Epeius Biotechnologies Corporation News

News items related to Epeius Biotechnologies Corporation as issued by the Send2Press Newswire service on behalf of the noted news source.

Phase I/II Study of Targeted Gene Delivery In Vivo – Intravenous Infusions of REXIN-G

Thu, 29 May 2008, 13:19:21 EDT | From: Epeius Biotechnologies Corporation

SAN MARINO, Calif., May 29 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007).

TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

Thu, 22 May 2008, 12:46:02 EDT | From: Epeius Biotechnologies Corporation

SAN MARINO, Calif., May 22 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week.

Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine

Tue, 18 Dec 2007, 10:58:09 EDT | From: Epeius Biotechnologies Corporation

SAN MARINO, Calif. – Dec. 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled ‘In Vivo Barriers to Gene Delivery’ was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.